BIIB News 310.72 06/12/2014 04:30:36 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 310.72 $BIIB

Watch for Biogen Idec to Potentially Rebound After Falling 1.50% Yesterday
Comtex SmarTrend(R) - Wed Jun 11, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $308.00 to a high of $314.99. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $312.61 on volume of 884,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.50% Sell Off
Comtex SmarTrend(R) - Wed Jun 11, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $308.00 to a high of $314.99. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $312.61 on volume of 884,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful

FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - Wed Jun 11, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.

RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology
Business Wire - Wed Jun 11, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.

Why the Future Is Bright for Isis Pharmaceuticals
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 5:30PM CDT
Isis Pharmaceuticals shares have surged this past week on news that it has received two milestone payments for advancing new drugs into phase 1 trials. Those milestone payments from Biogen   and AstraZeneca   successfully shifted attention away...

Up 37%: Can Receptos Compete With Novartis?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 10, 5:15PM CDT
Receptos  shareholders had a great day today, with the stock up 37% on exciting phase 2 data for its lead drug candidate RPC1063 in multiple sclerosis. And with a phase 3 trial pitting RPC1063 against Biogen Idec 's Avonex ongoing, there is some...

Can Receptos' New Drug Beat Biogen?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
Receptos shares surged by a 36% this morning following news that the company's RPC1063 met its primary endpoint as a treatment for relapsing multiple sclerosis. The midstage trial results offer investors hope that Receptos' product will...

Isis Pharma Earns Milestone Payment on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 10:30AM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a milestone payment of $14 million from Biogen with the initiation of a phase I study on ISIS-DMPKRx for the treatment of myotonic dystrophy type I (DM1).

The Pulmonary Fibrosis Foundation Receives Grant From Biogen Idec To Support The PFF Patient Registry
PR Newswire - Tue Jun 10, 10:00AM CDT
The Pulmonary Fibrosis Foundation (PFF) today announced a key partnership with Biogen Idec in support of the PFF Patient Registry. The PFF announced its plan to establish a PFF Patient Registry, along with a PFF Care Center Network (CCN), at its biennial PFF Summit held in December 2013.

Lupus Nephritis - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fdzqtl/lupus_nephritis) has announced the addition of the "Lupus Nephritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Bristol-Myers Squibb Company - Baxter International Inc. - Johnson & Johnson - Biogen Idec Inc. - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Noxxon Pharma AG - Anthera Pharmaceuticals Inc. - Kadmon Pharmaceuticals, LLC - Azano Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/fd..._nephritis

Biogen's Eloctate Approved in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 12:50PM CDT
The FDA approved Biogen's (BIIB) hemophilia A treatment, Eloctate, which will be launched in July.

By End of 2018 the Global Protein Therapeutics Market is Estimated to Reach US$ 165 Billion as New Products Enter the Sector
M2 - Mon Jun 09, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3s8lj/global_protein) has announced the addition of the "Global Protein Therapeutics Market Outlook 2018" report to their offering. According to this new research report, Global Protein Therapeutics Market Outlook 2018, a large number of market players has been developing monoclonal antibodies (mAbs). This research has found that mAbs contribute the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments. The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performances and last but not the least, current and future market sizes. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance. Companies Mentioned: - Abbott Laboratories - Amgen Inc. - Biogen Idec Inc. - Eli Lilly & Company - Johnson & Johnson - Merck Serono S.A. - Novo Nordisk - Pfizer - Roche Group - Sanofi-Aventis For more information visit http://www.researchandmarkets.com/research/c3...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Stock Indexes Slightly Up; Apple Split Takes Effect
at Investor's Business Daily - Mon Jun 09, 9:27AM CDT
Stocks hovered modestly above the break-even line in early trading Monday. The Nasdaq, S&P 500 and Dow Jones industrial average were up 0.1% each. Volume in the stock market today was running higher on the Nasdaq and lower on the NYSE vs. Friday's...

Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1
PR Newswire - Mon Jun 09, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-DMPKRx. Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement. ISIS-DMPKRx is designed to reduce the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type 1 (DM1).

Global Protein Therapeutics Market 2012-2016: CAGR, Market Size, Forecasts till 2016
M2 - Mon Jun 09, 4:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gvn6gl/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. However, patent-expiration of top-selling drugs could pose a challenge to the growth of this market. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/gv...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Chronic Lymphocytic Leukaemia (CLL) Therapeutics Market Investigated by FirstWord in In-demand Report Published at MarketPublishers.com
PRWeb - Mon Jun 09, 3:34AM CDT
Chronic lymphocytic leukaemia (CLL) is the most common type of the leukaemias. Nevertheless, until recently, it has been underserved in terms of effective therapeutic options. However, a revolution in targeted and personalized therapies is tremendously altering the treatment algorithm and also spurs the development of the CLL therapeutic market. The list of the marketed CLL drugs includes Rituxan/MabThera, Arzerra, Gazyva, Campath/MabCampath and Imbruvica. Meanwhile, pipeline drugs include idelalisib, ABT-199, IPI-145, Revlimid, and alvocidib.

The US Food and Drug Administration (FDA) approves Eloctate(TM)
Thomson Reuters ONE - Mon Jun 09, 1:02AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) partner Biogen Idechas announced that the US Food and Drug Administration (FDA) has approved Eloctate [Antihaemophilic Factor VIII (Recombinant), Fc Fusion Protein] for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with haemophilia A.This is the first regulatory approval worldwide for Eloctate and the therapy is currently under review by regulatory authorities in several other countries including Canada, Australia and Japan.

This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

3 Spectacular Ways Samsung Could Disrupt the Health Care Industry
Leo Sun, The Motley Fool - Motley Fool - Sat Jun 07, 10:05AM CDT
When most investors think of Samsung , they inevitably think of smartphones, tablets, and TVs. Yet over the past several years, Samsung has also beefed up its presence in the health care industry through investments in medical devices,...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 0

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 51

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 326

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 349

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 11

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 483

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 197

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Integer Holdings Opens Conversion on 2.125% Senior Notes

Updated Category News Views 151

Integer Holdings Announces Conversion of Senior Notes Integer Holdings Corporation (NYSE: ITGR) has recently made headlines with the announcement that its 2.125% Convertible Senior Notes, due in 2028, are now eligible for conversion. This pivotal move allows holders to convert their notes into either cash, common stock, or a combination of both. The option to convert is...

Continue Reading
Investors Urged to Consider Class Action Against Micron Technology

Updated Category News Views 119

Class Action Lawsuit Against Micron Technology, Inc. Levi & Korsinsky, LLP has alerted investors in Micron Technology, Inc. (NASDAQ: MU) regarding an ongoing class action securities lawsuit. This legal action aims to represent those investors who may have incurred financial losses during a specified period. Investors are encouraged to stay informed regarding this...

Continue Reading
Expansion Grant from Bradford White Boosts ECA Internship Program

Updated Category News Views 88

Bradford White Fuels Growth in ECA Internship Program Bradford White Corporation, known for its innovative water heating solutions, has committed $50,000 towards expanding the Energy Coordinating Agency's (ECA) internship program focused on heat pump technology. This initiative aims to enhance training opportunities for the next generation of plumbing and HVAC...

Continue Reading
Industrial Automation Market Set for Significant Growth Ahead

Updated Category News Views 199

Transformations in the Industrial Automation Market Landscape The industrial automation sector is undergoing a major shift as manufacturers worldwide increasingly adopt Industry 4.0 technologies and artificial intelligence. This evolution is spurred by pressing challenges including labor shortages and the need for enhanced operational efficiency. The market is projected...

Continue Reading
Exploring Competitive Landscape of Amazon.com in Retail Sector

Updated Category News Views 159

Understanding Amazon.com's Competitive Position In today's dynamic business world, understanding how companies perform against their competitors is essential. This article delves into a detailed examination of Amazon.com (NASDAQ: AMZN) and compares it with key rivals in the broadline retail sector. By exploring crucial financial data, market strategies, and growth...

Continue Reading